Parabilis Medicines, Inc. Common Stock (NASDAQ:PBLS) — Market Cap & Net Worth
Market Cap & Net Worth: Parabilis Medicines, Inc. Common Stock (PBLS)
Parabilis Medicines, Inc. Common Stock (NASDAQ:PBLS) has a market capitalization of $3.35 Billion ($3.35 Billion) as of October 13, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4580 globally and #1563 in its home market, demonstrating a -9.72% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Parabilis Medicines, Inc. Common Stock's stock price $27.48 by its total outstanding shares 121952030 (121.95 Million).
Parabilis Medicines, Inc. Common Stock Market Cap History: 2026 to 2026
Parabilis Medicines, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $3.35 Billion to $3.35 Billion (0.00% CAGR). Check PBLS stock price and chart for real-time trading data and today's change.
Parabilis Medicines, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Parabilis Medicines, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see PBLS cash flow metrics for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PBLS by Market Capitalization
Companies near Parabilis Medicines, Inc. Common Stock in the global market cap rankings as of October 13, 2026. See Parabilis Medicines, Inc. Common Stock (PBLS) balance sheet quality index to understand what proportion of total assets are financed by equity.
Key companies related to Parabilis Medicines, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
Parabilis Medicines, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Parabilis Medicines, Inc. Common Stock's market cap moved from $3.35 Billion to $ 3.35 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.35 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 12th, 2026 the market cap of Parabilis Medicines, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.35 Billion USD |
| MoneyControl | $3.35 Billion USD |
| MarketWatch | $3.35 Billion USD |
| marketcap.company | $3.35 Billion USD |
| Reuters | $3.35 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Parabilis Medicines, Inc. Common Stock
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein … Read more